Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Myocardial infarction? 203 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 203 reports of Myocardial infarction have been filed in association with OCRELIZUMAB (OCREVUS). This represents 0.4% of all adverse event reports for OCRELIZUMAB.

203
Reports of Myocardial infarction with OCRELIZUMAB
0.4%
of all OCRELIZUMAB reports
25
Deaths
117
Hospitalizations

How Dangerous Is Myocardial infarction From OCRELIZUMAB?

Of the 203 reports, 25 (12.3%) resulted in death, 117 (57.6%) required hospitalization, and 9 (4.4%) were considered life-threatening.

Is Myocardial infarction Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 203 reports have been filed with the FAERS database.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Myocardial infarction?

ROSIGLITAZONE (17,018) TESTOSTERONE (3,396) ADALIMUMAB (3,214) SACUBITRIL\VALSARTAN (3,120) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (2,391) APIXABAN (2,010) TICAGRELOR (1,749) LENALIDOMIDE (1,712) ETANERCEPT (1,693) METFORMIN\ROSIGLITAZONE (1,640)

Which OCRELIZUMAB Alternatives Have Lower Myocardial infarction Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Myocardial infarction Reports All Drugs Causing Myocardial infarction OCRELIZUMAB Demographics